A Randomized, Double-blind, Placebo-controlled Phase 2a Study to Evaluate the Safety and Immunogenicity of Seasonal Influenza Vaccine and Ad26.RSV.preF, With and Without Co-administration, in Adults Aged 60 Years and Older in Stable Health
Phase of Trial: Phase II
Latest Information Update: 19 Sep 2018
At a glance
- Drugs Influenza virus vaccine (Primary) ; JNJ 64400141 (Primary)
- Indications Respiratory syncytial virus infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Janssen Vaccines and Prevention B.V
- 31 Aug 2018 Status changed from active, no longer recruiting to completed.
- 27 Feb 2018 Status changed from recruiting to active, no longer recruiting.
- 02 Jan 2018 Planned End Date changed from 5 Jul 2018 to 13 Jul 2018.